< 1 minute read
Oct. 6, 2021
BAY-8400: An Oral Selective DNA-PK Kinase Inhibitor
BAY-8400
oral selective DNA-PK kinase inhibitor synergy with radiotherapy in model from library screen Journal of Medicinal Chemistry Bayer AG, Berlin, Germany
Loading...
